Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL)
Publication date: Available online 2 November 2026 Source: Clinical Lymphoma Myeloma and Leukemia Author(s): Francesca Maria Quaglia, Maria Elena Carazzolo, Antonino Aparo, Alice Parisi, Luisa Lorenzi, Barbara Famengo, Maurilio Ponzoni, Emma Albertini, Riccardo Moia, Francesco Piazza, Alessandro Re, Maria Chiara Tisi, Luca Nassi, Piero Bulian, Alessia Castellino, Vittorio Ruggero Zilioli, Piero Maria Stefani, Alberto Fabbri, Elisa Lucchini, Annalisa Arcari
Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL). // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026040243?dgcid=rss_sd_all
Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL). Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026040243?dgcid=rss_sd_all
“Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL).” Clinical Lymphoma, Myeloma & Leukemia.
@article{article40970,
title = {Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL)},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026040243?dgcid=rss_sd_all}
}